Gürbüz, M. Et Al. 2022. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine , vol.101, no.50 .

Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... Paydaş, S.(2022). Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine , vol.101, no.50.

Gürbüz, Mustafa Et Al. "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group," Medicine , vol.101, no.50, 2022

Gürbüz, Mustafa Et Al. "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group." Medicine , vol.101, no.50, 2022

Gürbüz, M. Et Al. (2022) . "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group." Medicine , vol.101, no.50.

@article{article, author={Mustafa Gürbüz Et Al. }, title={Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group}, journal={Medicine}, year=2022}